

Development of First-in-Class NK Cell Engagers Targeting Trop-2/NKp46 Incorporating ADCC Maximizing Fc Variants for the Treatment of Triple-Negative Breast Cancer

Korea University



ONCOLOGY	Hit
Product Type	NK cell engager
Indication	Triple-negative breast cancer (TNBC)
Target	Trop-2, NKp46 and CD16A
MoA(Mechanism of Action)	Maximized NK cell activation → Efficient clearance of Trop-2 expressed TNBC
Competitiveness	First-in-Class <ul style="list-style-type: none"> • Trop-2 target NK cell engager. • Maximized NK cell recruitment through CD16A×NKp46×B7-H6. • Bispecific antibody format that can be produced by simple bioprocessing steps.
Development Stage	Hit
Route of Administration	Intravenous